Biomedical Engineering Reference
In-Depth Information
Bansal T, Akhtar N, Jaggi M, Khar RK, Talegaonkar S (2009) Novel formulation approaches for
optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov Today
14 (21-22):1067-1074. doi:S1359-6446(09)00254-2 [pii] 10.1016/j.drudis.2009.07.010
Bansal T, Jaggi M, Khar RK, Talegaonkar S (2009) Emerging significance of flavonoids as
P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci 12 (1):46-78
Bardelmeijer HA, van Tellingen O, Schellens JH, Beijnen JH (2000) The oral route for the adminis-
tration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.
Invest New Drugs 18 (3):231-241
Bardelmeijer HA, Beijnen JH, Brouwer KR, Rosing H, Nooijen WJ, Schellens JH, van Tellingen
O (2000) Increased oral bioavailability of paclitaxel by GF120918 in mice through selective
modulation of P-glycoprotein. Clin Cancer Res 6 (11):4416-4421
Barrett JS, Szego P, Rohatagi S, Morales RJ, De Witt KE, Rajewski G, Ireland J (1996) Absorption
and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointes-
tinal tract in healthy males. Pharm Res 13 (10):1535-1540
Batrakova EV, Kabanov AV (2008) Pluronic block copolymers: evolution of drug delivery concept
from inert nanocarriers to biological response modifiers. J Control Release 130 (2):98-106.
doi:S0168-3659(08)00221-6 [pii] 10.1016/j.jconrel.2008.04.013
Batrakova EV, Li S, Alakhov VY, Miller DW, Kabanov AV (2003) Optimal structure requirements
for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in
bovine brain microvessel endothelial cells. J Pharmacol Exp Ther 304 (2):845-854.
doi:10.1124/jpet.102.043307
Benet LZ, Cummins CL, Wu CY (2004) Unmasking the dynamic interplay between efflux trans-
porters and metabolic enzymes. Int J Pharm 277 (1-2):3-9. doi:10.1016/j.ijpharm.2002.12.002
S0378517304001255 [pii]
Bernkop-Schnurch A, Schmitz T (2007) Presystemic metabolism of orally administered peptide
drugs and strategies to overcome it. Curr Drug Metab 8 (5):509-517
Blanchette J, Kavimandan N, Peppas NA (2004) Principles of transmucosal delivery of thera-
peutic agents. Biomed Pharmacother 58 (3):142-151. doi:10.1016/j.biopha.2004.01.006
S0753332204000228 [pii]
Blattman JN, Greenberg PD (2004) Cancer immunotherapy: a treatment for the masses. Science
305 (5681):200-205. doi:10.1126/science.1100369 305/5681/200 [pii]
Boddy AV, Yule SM (2000) Metabolism and pharmacokinetics of oxazaphosphorines. Clin
Pharmacokinet 38 (4):291-304
Boobis AR, Davies DS (1984) Human cytochromes P-450. Xenobiotica 14 (1-2):151-185.
doi:10.3109/00498258409151404
Brayden DJ (2001) Oral vaccination in man using antigens in particles: current status. Eur J Pharm
Sci 14 (3):183-189. doi:S0928098701001750 [pii]
Breedveld P, Beijnen JH, Schellens JH (2006) Use of P-glycoprotein and BCRP inhibitors to
improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci
27 (1):17-24. doi:S0165-6147(05)00310-X [pii] 10.1016/j.tips.2005.11.009
Buggins TR, Dickinson PA, Taylor G (2007) The effects of pharmaceutical excipients on drug
disposition. Adv Drug Deliv Rev 59 (15):1482-1503
Cai Z, Wang Y, Zhu LJ, Liu ZQ (2010) Nanocarriers: a general strategy for enhancement of oral
bioavailability of poorly absorbed or pre-systemically metabolized drugs. Curr Drug Metab 11
(2):197-207
Chadwick S, Kriegel C, Amiji M (2010) Nanotechnology solutions for mucosal immunization. Adv
Drug Deliv Rev 62 (4-5):394-407. doi:S0169-409X(09)00353-6 [pii] 10.1016/j.addr.2009.11.012
Chakraborty S, Shukla D, Mishra B, Singh S (2009) Lipid--an emerging platform for oral delivery
of drugs with poor bioavailability. Eur J Pharm Biopharm 73 (1):1-15. doi:S0939-6411(09)
00166-0 [pii] 10.1016/j.ejpb.2009.06.001
Chen W, Patel GB, Yan H, Zhang J (2010) Recent advances in the development of novel mucosal
adjuvants and antigen delivery systems. Hum Vaccin 6 (9). doi:11561 [pii]
Clark MA, Jepson MA, Hirst BH (2001) Exploiting M cells for drug and vaccine delivery. Adv
Drug Deliv Rev 50 (1-2):81-106. doi:S0169-409X(01)00149-1 [pii]
Search WWH ::
Custom Search